BSE: 0 | NSE: QUESTLAB | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Quest Laboratories Ltd is a average quality company.
The key valuation ratios of Quest Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Quest Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 12.3% | 55% | 46.5% | 57.5% | - |
| Value Creation Index ⓘ | -0.1 | 2.9 | 2.3 | 3.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 30.4 | 59.5 | 61.6 | 82.6 | 83 |
| Sales YoY Gr. | - | 95.9% | 3.6% | 33.9% | - |
| Adj EPS ⓘ | 0.6 | 3.8 | 4.6 | 8.5 | 6.2 |
| YoY Gr. | - | 547.5% | 20.4% | 83.9% | - |
| BVPS (₹) ⓘ | 5.5 | 9.3 | 14 | 24 | 43.8 |
| Adj Net Profit ⓘ | 0.6 | 4.1 | 5 | 10.1 | 10 |
| Cash Flow from Ops. ⓘ | 1.1 | 3.5 | 3.9 | 3 | - |
| Debt/CF from Ops. ⓘ | 2.9 | 0.9 | 1.1 | 1.7 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 39.6% | 33.9% | ||||
| Adj EPS ⓘ | NA | NA | 142.9% | 83.9% | ||||
| BVPSⓘ | NA | NA | 63.8% | 71.4% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 10.8 | 51.9 | 39.5 | 46.2 | 18.2 |
| Op. Profit Mgn % ⓘ | 4.7 | 10.9 | 12.7 | 18.9 | NAN |
| Net Profit Mgn % ⓘ | 2.1 | 6.9 | 8 | 12.2 | 12.2 |
| Debt to Equity ⓘ | 0.5 | 0.3 | 0.3 | 0.2 | - |
| Working Cap Days ⓘ | 0 | 116 | 186 | 190 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 13 | 10 | 31 | 0 |
Sales growth is growing at healthy rate in last 3 years 39.58%
Net Profit is growing at healthy rate in last 3 years 142.94%
Return on Equity has declined versus last 3 years average to 18.20%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 6.2 | - |
| TTM Sales (₹ Cr.) | 82.6 | - |
| BVPS (₹.) ⓘ | 43.8 | - |
| Reserves (₹ Cr.) ⓘ | 55 | - |
| P/BV ⓘ | 2.51 | - |
| PE ⓘ | 17.86 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 180 |
| Equity (₹ Cr.) | 16.4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 30 | 59 | 62 | 83 |
| Operating Expenses ⓘ | 29 | 53 | 54 | 67 |
| Manufacturing Costs | 1 | 1 | 1 | 1 |
| Material Costs | 24 | 44 | 42 | 52 |
| Employee Cost | 3 | 3 | 3 | 3 |
| Other Costs ⓘ | 1 | 4 | 8 | 10 |
| Operating Profit ⓘ | 1 | 6 | 8 | 16 |
| Operating Profit Margin (%) | 4.7% | 10.9% | 12.7% | 18.8% |
| Other Income ⓘ | 0 | 0 | 0 | 0 |
| Interest ⓘ | 0 | 0 | 1 | 1 |
| Depreciation ⓘ | 0 | 0 | 1 | 1 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 6 | 7 | 14 |
| Tax ⓘ | 0 | 2 | 2 | 4 |
| Profit After Tax | 1 | 4 | 5 | 10 |
| PAT Margin (%) | 2.2% | 6.9% | 8.2% | 12.2% |
| Adjusted EPS (₹) | 0.6 | 3.8 | 4.7 | 8.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 6 | 10 | 15 | 29 | ||||||
| Share Capital ⓘ | 1 | 1 | 1 | 12 | ||||||
| Reserves ⓘ | 5 | 9 | 14 | 17 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 3 | 3 | 4 | 5 | ||||||
| Long Term Debt | 1 | 1 | 2 | 1 | ||||||
| Short Term Debt | 2 | 2 | 2 | 4 | ||||||
| Trade Payables | 8 | 17 | 25 | 20 | ||||||
| Others Liabilities ⓘ | 2 | 5 | 3 | 6 | ||||||
| Total Liabilities ⓘ | 18 | 35 | 47 | 59 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 8 | 10 | 13 | 14 | ||||||
| Accumulated Depreciation | 2 | 3 | 3 | 4 | ||||||
| Net Fixed Assetsⓘ | 6 | 7 | 10 | 10 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | ||||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | ||||||
| Inventories | 1 | 1 | 11 | 16 | ||||||
| Trade Receivables | 9 | 22 | 20 | 23 | ||||||
| Cash Equivalents | 0 | 2 | 0 | 0 | ||||||
| Others Assetsⓘ | 2 | 3 | 6 | 9 | ||||||
| Total Assets ⓘ | 18 | 35 | 47 | 59 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 1 | 3 | 4 | 3 |
| PBT ⓘ | 1 | 6 | 7 | 14 |
| Adjustment ⓘ | 1 | 1 | 1 | 1 |
| Changes in Working Capital ⓘ | -0 | -3 | -2 | -8 |
| Tax Paid ⓘ | 0 | 0 | -2 | -4 |
| Cash Flow From Investing Activity ⓘ | -1 | -2 | -4 | -5 |
| Capex | -1 | -2 | -3 | -1 |
| Net Investments | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | -1 | -4 |
| Cash Flow From Financing Activityⓘ | 0 | 0 | 0 | 2 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 3 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 1 | -1 |
| Interest Paid ⓘ | 0 | 0 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 |
| Net Cash Flow ⓘ | 0 | 1 | 0 | 0 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 11.12 | 51.69 | 40.21 | 46.15 | ||||||
| ROCE (%) | 12.28 | 55 | 46.54 | 57.48 | ||||||
| Asset Turnover Ratio | 1.65 | 2.24 | 1.51 | 1.55 | ||||||
| PAT to CFO Conversion(x) | 1 | 0.75 | 0.8 | 0.3 | Working Capital Days | |||||
| Receivable Days | 110 | 96 | 124 | 96 | ||||||
| Inventory Days | 10 | 6 | 36 | 60 | ||||||
| Payable Days | 119 | 103 | 182 | 154 | ||||||
Quest Laboratories Limited was originally incorporated under the name ‘Quest Laboratories Private Limited’ under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated June 01, 1998, issued by the Registrar of Companies Madhya Pradesh, Gwalior. Subsequently, the status of the Company was changed to public limited and the name of Company was changed to ‘Quest Laboratories Limited’ vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of its Company held on January 11, 2024. The fresh certificate of incorporation consequent to conversion was issued on January 23, 2024, by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Centralised Processing Centre.
Quest Laboratories is engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark ‘Quest Laboratories’. The company produces a variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. This comprehensive approach allows the Company to address a wide range of medical needs and preferences among patients.
The Company holds World Health Orgabnization (WHO) Schedule M GMP, and GLP certifications, adhering to the stringent guidelines set by the World Health Organization. Its commitment to quality is further demonstrated by its ISO 9001:2015 certification and ISO/IEC 17025:2017 accreditation. With manufacturing under one roof, the company maintains stringent quality control standards throughout the entire manufacturing process. By doing so, it ensures that its products meet the relevant quality standards before they reach the market.
The company also possesses Good Laboratory Practice (GLP) certificate issued by Food & Drug Administration, Bhopal, Madhya Pradesh, indicating its commitment to maintaining high standards of quality and compliance in laboratory operations, particularly within the pharmaceutical sector. Its in-house laboratory is equipped with various equipment such as HPLC (High-Performance Liquid Chromatography), GC (Gas Chromatography), FTIR (Fourier Transform Infrared Spectroscopy), UV (Ultraviolet-Visible Spectroscopy), Dissolution apparatus, and other advanced instruments. This comprehensive suite of tools enables it to conduct a wide array of tests and analyses efficiently and accurately.
Business area of the company
The company is primarily engaged in the manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. The company also produces variety of products, comprising ethical drugs, generic drugs, and over-the-counter drugs (OTC).
Products of the company
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
